Rohto Pharmaceutical×KOSE Holdings
Different ways of making money, on the same scale.
Same yardstick
| Metric | Rohto PharmaceuticalFY ending Mar 2026 | KOSE HoldingsFY ending Dec 2025 |
|---|---|---|
| Revenue | ¥343.7B | ¥330.2B |
| COGS ratio | 43.9% | 31.0% |
| Operating margin | 12.0% | 5.6% |
| Net margin | 10.0% | 4.6% |
| FCF margin | 6.3% | -3.1% |
Highlighted = best value for that metric
Compare industry percentiles by axis
Each row uses the same 0–100 scale. Dots show each company's rank within its primary industry.
- Rohto PharmaceuticalPrimary industry: Cosmetics
- KOSE HoldingsPrimary industry: Cosmetics
CompanyRank
Revenue growth
- Rohto Pharmaceutical65.922 peers
- KOSE HoldingsN/A
- Rohto Pharmaceutical
Profitability
- Rohto Pharmaceutical86.526 peers
- KOSE Holdings44.226 peers
- Rohto Pharmaceutical
Cash conversion
- Rohto Pharmaceutical61.422 peers
- KOSE Holdings11.422 peers
- Rohto Pharmaceutical
Efficiency
- Rohto Pharmaceutical21.226 peers
- KOSE Holdings36.526 peers
- Rohto Pharmaceutical
Financial strength
- Rohto PharmaceuticalN/A
- KOSE HoldingsN/A
- Rohto Pharmaceutical
Each dot is a company's percentile within its primary industry; peer groups may differ. Missing axes are labeled as unavailable. No combined score is calculated, and industry rank is not an investment recommendation.
Money flows side by side
Chart height is proportional to revenue.
Rohto Pharmaceutical¥343.7B · keeps ¥12 per ¥100
KOSE Holdings¥330.2B · keeps ¥6 per ¥100
Analyze this page with AI
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.